1.225

8.23% 0.095

Pacific Biosciences Of California Inc (PACB)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PACB? Forum Prognose

Schlusskurs vom Vortag:

$1.13

Offen:

$1.12

24-Stunden-Volumen:

6.56M

Relative Volume:

0.62

Marktkapitalisierung:

$323.16M

Einnahmen:

$188.87M

Nettoeinkommen (Verlust:

$-400.38M

KGV:

-0.8167

EPS:

-1.5

Netto-Cashflow:

$-260.90M

1W Leistung:

-3.70%

1M Leistung:

-15.66%

6M Leistung:

-25.43%

1J Leistung:

-64.13%

1-Tages-Spanne:

$1.12

$1.27

1-Wochen-Bereich:

$1.08

$1.36

52-Wochen-Spanne:

$1.08

$3.70

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Firmenname

Pacific Biosciences Of California Inc

Sektor

Healthcare (1165)

Branche

Medical Devices (161)

Telefon

650-521-8000

Adresse

1305 O'BRIEN DRIVE, MENLO PARK, CA

Mitarbeiter

796

Twitter

@pacbio

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PACB's Discussions on Twitter

Vergleichen Sie PACB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PACB Pacific Biosciences Of California Inc	1.225	323.16M	188.87M	-400.38M	-260.90M	-1.50
ABT Abbott Laboratories	131.57	225.32B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	100.40	149.74B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	373.52	142.48B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	88.49	113.49B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	71.96	42.10B	5.72B	4.17B	259.90M	6.97

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-11	Herabstufung	UBS	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Buy
2024-04-22	Herabstufung	JP Morgan	Overweight → Neutral
2024-04-18	Herabstufung	Goldman	Buy → Neutral
2023-12-14	Eingeleitet	Guggenheim	Neutral
2023-12-14	Eingeleitet	Stephens	Overweight
2023-12-13	Eingeleitet	Wolfe Research	Peer Perform
2023-11-17	Hochstufung	UBS	Neutral → Buy
2023-10-31	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Eingeleitet	Bernstein	Outperform
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-06-30	Eingeleitet	Goldman	Buy
2023-05-10	Eingeleitet	Barclays	Equal Weight
2023-03-31	Hochstufung	TD Cowen	Market Perform → Outperform
2023-02-02	Eingeleitet	UBS	Neutral
2023-01-20	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-01-21	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-01-06	Fortgesetzt	Piper Sandler	Neutral
2021-10-15	Fortgesetzt	Cowen	Market Perform
2021-09-27	Eingeleitet	Canaccord Genuity	Buy
2021-02-11	Hochstufung	Piper Sandler	Neutral → Overweight
2020-11-03	Herabstufung	Piper Sandler	Overweight → Neutral
2020-10-02	Hochstufung	JP Morgan	Neutral → Overweight
2020-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2020-06-02	Fortgesetzt	Cantor Fitzgerald	Overweight
2020-03-09	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-10-15	Hochstufung	Piper Jaffray	Neutral → Overweight
2019-04-02	Herabstufung	Stephens	Overweight → Equal-Weight
2018-10-19	Eingeleitet	Cowen	Outperform
2017-11-03	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Herabstufung	CL King	Buy → Neutral
2016-11-03	Bestätigt	Cantor Fitzgerald	Buy
2016-06-27	Eingeleitet	CL King	Buy
2016-04-15	Eingeleitet	First Analysis Sec	Overweight
2016-02-04	Herabstufung	Piper Jaffray	Overweight → Neutral
2016-01-04	Bestätigt	Cantor Fitzgerald	Buy
2015-10-23	Hochstufung	Piper Jaffray	Neutral → Overweight
2015-08-27	Eingeleitet	Cantor Fitzgerald	Buy
2015-02-04	Bestätigt	Maxim Group	Buy
2013-09-26	Bestätigt	Maxim Group	Buy
2013-01-14	Bestätigt	Maxim Group	Buy

Alle ansehen

Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten

Mar 28, 2025

Pacific Biosciences of California appoints CFO - MSN

Mar 28, 2025

Mar 27, 2025

PacBio names Jim Gibson as new CFO By Investing.com - Investing.com South Africa

Mar 27, 2025

Tech Giant CFO Who Raised $1B+ Joins PacBio: Ex-Tesla, Apple Executive to Drive Growth - Stock Titan

Mar 27, 2025

Publications March 2025 - Pacific Biosciences

Mar 27, 2025

Mar 25, 2025

Assessing Pacific Biosciences: Insights From 6 Financial Analysts - Benzinga

Mar 25, 2025

Mar 24, 2025

ATTENTION PACB SHAREHOLDERS: Investors Who Lost Money on Pacific Biosciences of California, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire

Mar 24, 2025

Mar 23, 2025

Here's Why You Should Retain PacBio Stock in Your Portfolio Now - MSN

Mar 23, 2025

Mar 22, 2025

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga

Mar 22, 2025

Mar 21, 2025

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - MSN

Mar 21, 2025

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN

Mar 21, 2025

Mar 19, 2025

PacBio, Take2 Resolve DNA Sequencing Patent Infringement Dispute - Bloomberg Law

Mar 19, 2025

Mar 18, 2025

Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading? - Insider Monkey

Mar 18, 2025

10 Most Volatile Stocks Under $3 For Day Trading - Insider Monkey

Mar 18, 2025

Inspiring the next generation of scientists: How multidisciplinary science powers PacBio technology - Pacific Biosciences

Mar 18, 2025

Mar 17, 2025

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks - The Globe and Mail

Mar 17, 2025

Mar 14, 2025

Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance

Mar 14, 2025

ATTENTION PACB SHAREHOLDERS: Investors who lost money on Pacific Biosciences of California, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire

Mar 14, 2025

Pacific Biosciences secures extended lease with rent abatement By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 13, 2025